---
title: Moxifloxacin vs. Polytrim for Conjunctivitis
nct_id: NCT00581542
overall_status: COMPLETED
phase: PHASE4
sponsor: University of Rochester
study_type: INTERVENTIONAL
primary_condition: Conjunctivitis
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00581542.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00581542"
ct_last_update_post_date: 2016-01-18
last_seen_at: "2026-05-12T06:17:28.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Moxifloxacin vs. Polytrim for Conjunctivitis

**Official Title:** A Single Blinded Clinical Trial Comparing Polytrim Ophthalmic Solution and Moxifloxacin Ophthalmic Solution for Treatment of Conjunctivitis.

**NCT ID:** [NCT00581542](https://clinicaltrials.gov/study/NCT00581542)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 124
- **Lead Sponsor:** University of Rochester
- **Conditions:** Conjunctivitis
- **Start Date:** 2007-03
- **Completion Date:** 2012-03
- **CT.gov Last Update:** 2016-01-18

## Brief Summary

The purpose of the study is to compare the effect of Polytrim Ophthalmic Solution and Moxifloxacin Ophthalmic Solution in treating your child's pink eye. Both these medications are approved by the Food and Drug Administration, for treatment of conjunctivitis. This study will investigate if both of the medications are equally good.

## Eligibility

- **Minimum age:** 1 Year
- **Maximum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* 1 - 18 years of age with presumed bacterial conjunctivitis.

Exclusion Criteria:

* Previous antibiotics or to receive systemic antibiotic.
```

## Arms

- **Moxifloxacin Opthalmic solution** (ACTIVE_COMPARATOR)
- **Polymyxin B-trimethoprim opthalmic solution** (ACTIVE_COMPARATOR)

## Interventions

- **moxifloxacin** (DRUG) — 1-2 drops three times a day for 8-10 days.
- **polytrim** (DRUG) — 1-2 drops four times a day for 8-10 days.

## Primary Outcomes

- **Number of Participants With Normal Physical Examination of the Eye** _(time frame: 10 days)_

## Secondary Outcomes

- **Number of Participants With a Negative Bacterial Culture** _(time frame: 10 days)_

## Locations (1)

- University of Rochester, Rochester, New York, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university of rochester|rochester|new york|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00581542.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00581542*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*